Reversible Anticholinesterases Pipeline Insight Report 2018: Products by Developmental Stage, Product Type, Molecule Type, and Administration Route - ResearchAndMarkets.com

September 6, 2018

DUBLIN--(BUSINESS WIRE)--Sep 6, 2018--The “Reversible Anticholinesterases -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

‘Reversible Anticholinesterases - Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Reversible Anticholinesterases development.

Descriptive coverage of pipeline development activities for Reversible Anticholinesterases - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Reversible Anticholinesterases pipeline products by developmental stage, product type, molecule type, and administration route.

Key Topics Covered:

1. Report Introduction

2. Reversible Anticholinesterases - Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Reversible Anticholinesterases

4. Comparative Analysis

5. Reversible Anticholinesterases Pipeline Products in Clinical Stages

Product Description Research and Development Product Development Activities

6. Reversible Anticholinesterases Pipeline Products in Non-clinical Stages

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment: Active Products

Pipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type 8. Inactive Pipeline ProductsProduct DescriptionResearch and DevelopmentProduct Development ActivitiesReason for dormancy/discontinuation

Companies Mentioned

Axovant SciencesDeuteRxLuye PharmaRaptor Pharmaceutical CorpAnavex Life SciencesAstellas PharmaNovartisEisai Co LtdJanssen Pharmaceutical KKFor more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mgw9xz/reversible?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180906005911/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/06/2018 04:01 PM/DISC: 09/06/2018 04:01 PM


Update hourly